GoodRx, a website and app that tracks prescription drug prices and offers coupons, used pricing and usage data from drug manufacturer websites for its list. Using the official manufacturer list price, GoodRx calculated the yearly supply of each drug at its most common dosage. It excluded drugs administered by a healthcare provider.
The 10 most expensive drugs approved in 2018 and their primary indication:
1. Takhzyro — $573,820 (Hereditary angioedema)
2. Tegsedi — $449,800 (Hereditary polyneuropathy)
3. Vitrakvi — $399,069 (Solid tumors)
4. Tibsovo — $317,733 (Acute myeloid leukemia)
5. Galafold — $315,250 (Fabry disease)
6. Symdeko — $292,000 (Cystic fibrosis)
7. Xospata — $273,750 (Acute myeloid leukemia
8. Lobrena — $195,345 (Lung cancer)
9. Palynziq — $178,120 (Phenylketonuria)
10. Talzenna — $177,390 (Breast cancer)
Access the full report here.
More articles on pharmacy:
Insys execs guilty of opioid racketeering scheme
Walgreens shaking up C-suite
Generic drugmakers could thrive in a recession, Moody’s says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
